Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...

The HHS has announced a plan to reduce regulations, stating that, for every new regulation introduced, at least 10 existing regulations must be eliminated.

Zongertinib conferred a clinically meaningful benefit in patients with previously treated, advanced, HER2-mutant NSCLC in a phase 1 trial.

US News & World Report has released its new over-the-counter (OTC) medicine and health product rankings for 2025.